Participants identified to have intermediate tau biomarker levels and clinical symptoms of AD and who were on donanemab had a slowing of decline of 35% in iARDS and 36% in CDR-SB over 18 months [45]. This evidence concerns the gene MAPT and Alzheimer disease.